Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04793750 · ClinicalTrials.gov registry record · NA

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)

A NA study, sponsored by Johns Hopkins University.

Completed
Registry status
NA
Development phase
224
Enrollment target

NCT04793750: Completed NA study, sponsored by Johns Hopkins University.

NCT04793750 is a NA study that has completed, run by Johns Hopkins University. The registered enrollment target is 224 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04793750, a NA study, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
NA
Development phase
224 participants
Enrollment target

Study Summary

This study proposes to investigate the performance of existing and new technologies for HIV diagnosis, one of the key strategies for Ending the HIV Epidemic in the U.S. Current, Standard-of-Care (SOC) diagnostic techniques have extended turn-around-times (TATs) that result in loss of patients to follow up due to delays in laboratory procedures. In this scenario, patients that are at a high-risk for HIV have the potential to continue transmission, making it difficult to end the epidemic. Rapid, Point-of-Care (POC) HIV viral load (VL) testing alleviates this problem by reducing TATs that allow providers to test for HIV infection and link patients to antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) during the same clinical visit, and subsequently, suppress VL, prevent HIV infection, and reduce its transmission among high-risk populations. The study proposes that evaluating the performance of new and existing POC technologies is needed to provide updated information to HIV test providers operating in different populations and settings and improve linkage to HIV treatment and prevention services. The study hypothesizes that: A. Determining the performance characteristics of HIV POC tests will inform optimal testing strategies in different populations and settings B. The use of HIV RNA POC tests will improve linkage to HIV treatment and prevention services: i. Improve early diagnosis of HIV ii. Reduce the time to ART initiation iii. Facilitate timely and appropriate referral for prevention services

Primary Outcome

The primary outcome of the study was linkage to care rate, defined as having at least one in-person or telehealth interaction with a clinical team about HIV ART or PrEP within the study follow-up period.

Interventions

  • DIAGNOSTIC_TEST Cepheid GeneXpert HIV-1 Qual POC HIV VL test
  • DIAGNOSTIC_TEST DPP HIV-Syphilis test system
  • DIAGNOSTIC_TEST OraQuick

Trial Details

FieldValue
Enrollment Target 224 participants
Start Date 2021-08-18
Est. Completion 2025-03-31
Phase NA
Johns Hopkins University

1,448 total trials

What the finished NCT04793750 record still lists

NCT04793750 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).

The record links to 0 conditions, and to 3 interventions - of which Cepheid GeneXpert HIV-1 Qual POC HIV VL test is the first listed.

NCT04793750 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04793750 about?

NCT04793750 is a clinical study titled "Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)". This study proposes to investigate the performance of existing and new technologies for HIV diagnosis, one of the key strategies for Ending the HIV Epidemic in the U.S. Current, Standard-of-Care (SOC) diagnostic techniques have extended turn-around-times (TATs) that result in loss of patients to fol...

What is the current status of trial NCT04793750?

This trial is currently completed. It is a NA study. The enrollment target is 224 participants. The study started on 2021-08-18. Estimated completion is 2025-03-31.

What interventions are being tested in trial NCT04793750?

The interventions under investigation include: Cepheid GeneXpert HIV-1 Qual POC HIV VL test (DIAGNOSTIC_TEST), DPP HIV-Syphilis test system (DIAGNOSTIC_TEST), OraQuick (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04793750?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04793750's enrollment target sits among peer trials

224 478th of 2000 higher than 1,520 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02706561 · 224 participants · NA

    Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery

  • NCT04140344 · 224 participants · NA

    The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions

  • NCT04915183 · 224 participants · Phase 2

    Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

  • NCT05519878 · 224 participants · NA

    Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04793750, the US trial registry maintained by the National Library of Medicine. NCT04793750 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.